Kimberly Thompson serves as the vice president of therapeutics at MapLight Therapeutics, where she oversees the preclinical research and development programs with a focus on psychiatry and CNS disorders. She received her doctorate in neuroscience from the University of California, Los Angeles in 2006. During her graduate work with Kelsey Martin she was the recipient of a National Science Foundation Graduate Research Fellowship and studied synapse-to-nucleus signaling underlying transcription-dependent neuronal plasticity. She joined Karl Deisseroth’s lab at Stanford University for her postdoctoral training. As a NARSAD Young Investigator, Dr. Thompson expressed channelrhodopsin under the control of the activity-dependent c-fos promoter to achieve experience-dependent control over appetitive and aversive prefrontal cortical circuits. She joined Circuit Therapeutics as senior scientist in 2012 and rose to become the senior director of the drug discovery program. She developed the optogenetic platform for target discovery and led all external research collaborations with pharmaceutical partners.